Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Abstract
All ivermectin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19ivm.org COVID-19 treatment researchIvermectinIvermectin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2

Saha et al., Structural Chemistry, doi:10.1007/s11224-021-01776-0 (date from preprint)
Mar 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Ivermectin for COVID-19
4th treatment shown to reduce risk in August 2020
 
*, now with p < 0.00000000001 from 104 studies, recognized in 22 countries.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19ivm.org
In Silico analysis predicting that ivermectin has a large binding affinity for the SARS-CoV-2 spike protein. Three different computer modeling techniques show that ivermectin can inhibit SARS-CoV-2 entrance via hACE2.
68 preclinical studies support the efficacy of ivermectin for COVID-19:
Ivermectin, better known for antiparasitic activity, is a broad spectrum antiviral with activity against many viruses including H7N766, Dengue32,67,68, HIV-168, Simian virus 4069, Zika32,70,71, West Nile71, Yellow Fever72,73, Japanese encephalitis72, Chikungunya73, Semliki Forest virus73, Human papillomavirus52, Epstein-Barr52, BK Polyomavirus74, and Sindbis virus73.
Ivermectin inhibits importin-α/β-dependent nuclear import of viral proteins66,68,69,75, shows spike-ACE2 disruption at 1nM with microfluidic diffusional sizing33, binds to glycan sites on the SARS-CoV-2 spike protein preventing interaction with blood and epithelial cells and inhibiting hemagglutination36,76, shows dose-dependent inhibition of wildtype and omicron variants31, exhibits dose-dependent inhibition of lung injury56,61, may inhibit SARS-CoV-2 via IMPase inhibition32, may inhibit SARS-CoV-2 induced formation of fibrin clots resistant to degradation5, inhibits SARS-CoV-2 3CLpro49, may inhibit SARS-CoV-2 RdRp activity24, may minimize viral myocarditis by inhibiting NF-κB/p65-mediated inflammation in macrophages55, may be beneficial for COVID-19 ARDS by blocking GSDMD and NET formation77, shows protection against inflammation, cytokine storm, and mortality in an LPS mouse model sharing key pathological features of severe COVID-1954,78, may be beneficial in severe COVID-19 by binding IGF1 to inhibit the promotion of inflammation, fibrosis, and cell proliferation that leads to lung damage4, may minimize SARS-CoV-2 induced cardiac damage35,43, increases Bifidobacteria which play a key role in the immune system79, has immunomodulatory46 and anti-inflammatory65,80 properties, and has an extensive and very positive safety profile81.
Saha et al., 1 Mar 2021, preprint, 2 authors.
In Silico studies are an important part of preclinical research, however results may be very different in vivo.
This PaperIvermectinAll
The Binding mechanism of Ivermectin and levosalbutamol with spike protein of SARS-CoV-2
Joyanta Kumar Saha, Md. Jahir Raihan
doi:10.21203/rs.3.rs-160254/v1
In this study, we have investigated the binding mechanism of two FDA approved drugs (ivermectin and levosalbutamol) with the spike protein of SARs-CoV-2 using three different computational modeling techniques. Molecular docking results predict that ivermectin shows a large binding a nity for spike protein (-9.0 kcal/mol) compared to levosalbutamol (-4.1 kcal/mol). Ivermectin binds with GLN492, GLN493, GLY496 and TRY505 residues in the spike protein through hydrogen bonds and levosalbutamol binds with TYR453 and TYR505 residues. Using density functional theory (DFT) studies, we have calculated the binding energies between ivermectin and levosalbutamol with residues in spike protein which favor their binding are − 17.8 kcal/mol and − 20.08 kcal/mol, respectively. The natural bond orbital (NBO) charge analysis has been performed to estimate the amount of charge transfer that occurred by two drugs during interaction with residues. Molecular dynamics (MD) study con rms the stability of spike protein bound with ivermectin through RMSD and RMSF analyses. Three different computer modeling techniques reveal that ivermectin is more stable than levosalbutamol in the active site of spike protein where hACE2 binds. Therefore, ivermectin can be a suitable inhibitor for SARS-CoV-2 to enter into the human cell through hACE2.
References
Becke, Density-functional thermochemistry. III. The role of exact exchange, J Chem Phys
Berendsen, Postma, Van Gunsteren, Dinola, Haak, Molecular dynamics with coupling to an external bath, J Chem Phys
Best, Zhu, Shim, Lopes, Mittal et al., Optimization of the Additive CHARMM All-Atom Protein Force Field Targeting Improved Sampling of the Backbone ϕ, ψ and Side-Chain χ1 and χ2 Dihedral Angles, J Chem Theory Comput
Caly, Druce, Catton, Jans, Wagstaff, The FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in vitro, Antiviral Res
Essmann, Perera, Berkowitz, Darden, Lee et al., A smooth particle mesh Ewald method, J Chem Phys
Frisch, Trucks, Schlegel, Scuseria, Robb et al., jax/output/CommonHTML/fonts/TeX
Gorbalenya, Baker, Baric, De Groot, Drosten et al., Coronaviridae Study Group of the International Committee on Taxonomy of, The species Severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2, Nature Microbiology
Hagar, Ahmed, Aljohani, Alhaddad, Investigation of Some Antiviral N-Heterocycles as COVID 19 Drug: Molecular Docking and DFT Calculations, International Journal of Molecular Sciences
Jat, Khairwa, Levalbuterol versus albuterol for acute asthma: a systematic review and meta-analysis, Pulm Pharmacol Ther
Lee, Yang, Parr, Development of the Colle-Salvetti correlation-energy formula into a functional of the electron density, Phys Rev B
Morse, Lalonde, Xu, Liu, Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infections Caused by 2019-nCoV, ChemBioChem
Pronk, Páll, Schulz, Larsson, Bjelkmar et al., GROMACS 4.5: a high-throughput and highly parallel open source molecular simulation toolkit, Bioinformatics
Ragia, Manolopoulos, Inhibition of SARS-CoV-2 entry through the ACE2/TMPRSS2 pathway: a promising approach for uncovering early COVID-19 drug therapies, European Journal of Clinical Pharmacology
Saha, Hossain, Ghosh, DFT study of response mechanism and selectivity of poly(3,4-ethylenedioxythiophene) towards CO2 and SO2 as gas sensor, Struct Chem
Spackman, Yu, Morton, Parker, Bond et al., Bridging Crystal Engineering and Drug Discovery by Utilizing Intermolecular Interactions and Molecular Shapes in Crystals, Angew Chem Int Ed
Touret, Gilles, Barral, Nougairède, Van Helden et al., In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication, Sci Rep
Yang, Wang, COVID-19: a new challenge for human beings, Cell Mol Immunol
Yi, Sun, Ye, Ding, Liu et al., Key residues of the receptor binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 and neutralizing antibodies, Cell Mol Immunol
Yuan, Wang, Zhao, Chen, Yang et al., Structure-Based High-Throughput Epitope Analysis of Hexon Proteins in B and C Species Human Adenoviruses (HAdVs), PLOS ONE
{ 'indexed': {'date-parts': [[2024, 5, 3]], 'date-time': '2024-05-03T08:24:47Z', 'timestamp': 1714724687931}, 'reference-count': 19, 'publisher': 'Springer Science and Business Media LLC', 'issue': '5', 'license': [ { 'start': { 'date-parts': [[2021, 4, 12]], 'date-time': '2021-04-12T00:00:00Z', 'timestamp': 1618185600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}, { 'start': { 'date-parts': [[2021, 4, 12]], 'date-time': '2021-04-12T00:00:00Z', 'timestamp': 1618185600000}, 'content-version': 'vor', 'delay-in-days': 0, 'URL': 'https://www.springer.com/tdm'}], 'funder': [ { 'DOI': '10.13039/100004457', 'name': 'The World Academy of Sciences', 'doi-asserted-by': 'publisher', 'award': ['16-008 RG/CHE/AS_I – FR3240293317']}], 'content-domain': {'domain': ['link.springer.com'], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 10]]}, 'DOI': '10.1007/s11224-021-01776-0', 'type': 'journal-article', 'created': {'date-parts': [[2021, 4, 12]], 'date-time': '2021-04-12T09:03:30Z', 'timestamp': 1618218210000}, 'page': '1985-1992', 'update-policy': 'http://dx.doi.org/10.1007/springer_crossmark_policy', 'source': 'Crossref', 'is-referenced-by-count': 17, 'title': 'The binding mechanism of ivermectin and levosalbutamol with spike protein of SARS-CoV-2', 'prefix': '10.1007', 'volume': '32', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-5592-2577', 'authenticated-orcid': False, 'given': 'Joyanta Kumar', 'family': 'Saha', 'sequence': 'first', 'affiliation': []}, {'given': 'Md. Jahir', 'family': 'Raihan', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'published-online': {'date-parts': [[2021, 4, 12]]}, 'reference': [ { 'key': '1776_CR1', 'doi-asserted-by': 'publisher', 'first-page': '536', 'DOI': '10.1038/s41564-020-0695-z', 'volume': '5', 'author': 'AE Gorbalenya', 'year': '2020', 'unstructured': 'Gorbalenya AE, Baker SC, Baric RS, de Groot RJ, Drosten C, Gulyaeva AA, ' 'Haagmans BL, Lauber C, Leontovich AM, Neuman BW, Penzar D, Perlman S, ' 'Poon LLM, Samborskiy DV, Sidorov IA, Sola I, Ziebuhr J (2020) V. ' 'Coronaviridae Study Group of the International Committee on Taxonomy of, ' 'The species severe acute respiratory syndrome-related coronavirus: ' 'classifying 2019-nCoV and naming it SARS-CoV-2. Nat Microbiol 5:536–544', 'journal-title': 'Nat Microbiol'}, { 'key': '1776_CR2', 'doi-asserted-by': 'publisher', 'first-page': '555', 'DOI': '10.1038/s41423-020-0407-x', 'volume': '17', 'author': 'P Yang', 'year': '2020', 'unstructured': 'Yang P, Wang X (2020) COVID-19: a new challenge for human beings. Cell ' 'Mol Immunol 17:555–557', 'journal-title': 'Cell Mol Immunol'}, { 'key': '1776_CR3', 'doi-asserted-by': 'crossref', 'unstructured': 'Hagar M, Ahmed HA, Aljohani G, Alhaddad OA (2020) Investigation of some ' 'antiviral N-heterocycles as COVID 19 drug: molecular docking and DFT ' 'calculations. Int J Mol Sci 21', 'DOI': '10.3390/ijms21113922'}, { 'key': '1776_CR4', 'doi-asserted-by': 'publisher', 'first-page': '104787', 'DOI': '10.1016/j.antiviral.2020.104787', 'volume': '178', 'author': 'L Caly', 'year': '2020', 'unstructured': 'Caly L, Druce JD, Catton MG, Jans DA, Wagstaff KM (2020) The ' 'FDA-approved drug ivermectin inhibits the replication of SARS-CoV-2 in ' 'vitro. Antivir Res 178:104787', 'journal-title': 'Antivir Res'}, { 'key': '1776_CR5', 'doi-asserted-by': 'publisher', 'first-page': '621', 'DOI': '10.1038/s41423-020-0458-z', 'volume': '17', 'author': 'C Yi', 'year': '2020', 'unstructured': 'Yi C, Sun X, Ye J, Ding L, Liu M, Yang Z, Lu X, Zhang Y, Ma L, Gu W, Qu ' 'A, Xu J, Shi Z, Ling Z, Sun B (2020) Key residues of the receptor ' 'binding motif in the spike protein of SARS-CoV-2 that interact with ACE2 ' 'and neutralizing antibodies. Cell Mol Immunol 17:621–630', 'journal-title': 'Cell Mol Immunol'}, { 'key': '1776_CR6', 'doi-asserted-by': 'crossref', 'unstructured': 'Ragia G, Manolopoulos VG (2020) Inhibition of SARS-CoV-2 entry through ' 'the ACE2/TMPRSS2 pathway: a promising approach for uncovering early ' 'COVID-19 drug therapies. Eur J Clin Pharmacol', 'DOI': '10.1007/s00228-020-02963-4'}, { 'key': '1776_CR7', 'doi-asserted-by': 'publisher', 'first-page': '730', 'DOI': '10.1002/cbic.202000047', 'volume': '21', 'author': 'JS Morse', 'year': '2020', 'unstructured': 'Morse JS, Lalonde T, Xu S, Liu WR (2020) Learning from the past: ' 'possible urgent prevention and treatment options for severe acute ' 'respiratory infections caused by 2019-nCoV. ChemBioChem 21:730–738', 'journal-title': 'ChemBioChem'}, { 'key': '1776_CR8', 'doi-asserted-by': 'crossref', 'unstructured': 'S.S. Ahmad, M. Sinha, K. Ahmad, M. Khalid, I. Choi (2020) Study of ' 'Caspase 8 Inhibition for the Management of Alzheimer’s Disease: A ' 'Molecular Docking and Dynamics Simulation, Molecules, 25:2071.', 'DOI': '10.3390/molecules25092071'}, { 'key': '1776_CR9', 'doi-asserted-by': 'publisher', 'first-page': '13093', 'DOI': '10.1038/s41598-020-70143-6', 'volume': '10', 'author': 'F Touret', 'year': '2020', 'unstructured': 'Touret F, Gilles M, Barral K, Nougairède A, van Helden J, Decroly E, de ' 'Lamballerie X, Coutard B (2020) In vitro screening of a FDA approved ' 'chemical library reveals potential inhibitors of SARS-CoV-2 replication. ' 'Sci Rep 10:13093', 'journal-title': 'Sci Rep'}, { 'key': '1776_CR10', 'doi-asserted-by': 'publisher', 'first-page': '239', 'DOI': '10.1016/j.pupt.2012.11.003', 'volume': '26', 'author': 'KR Jat', 'year': '2013', 'unstructured': 'Jat KR, Khairwa A (2013) Levalbuterol versus albuterol for acute asthma: ' 'a systematic review and meta-analysis. Pulm Pharmacol Ther 26:239–248', 'journal-title': 'Pulm Pharmacol Ther'}, { 'key': '1776_CR11', 'doi-asserted-by': 'publisher', 'first-page': '5648', 'DOI': '10.1063/1.464913', 'volume': '98', 'author': 'AD Becke', 'year': '1993', 'unstructured': 'Becke AD (1993) Density-functional thermochemistry. III. The role of ' 'exact exchange. J Chem Phys 98:5648–5652', 'journal-title': 'J Chem Phys'}, { 'key': '1776_CR12', 'doi-asserted-by': 'publisher', 'first-page': '785', 'DOI': '10.1103/PhysRevB.37.785', 'volume': '37', 'author': 'C Lee', 'year': '1988', 'unstructured': 'Lee C, Yang W, Parr RG (1988) Development of the Colle-Salvetti ' 'correlation-energy formula into a functional of the electron density. ' 'Phys Rev B 37:785–789', 'journal-title': 'Phys Rev B'}, { 'key': '1776_CR13', 'doi-asserted-by': 'publisher', 'first-page': '1427', 'DOI': '10.1007/s11224-018-1272-4', 'volume': '30', 'author': 'JK Saha', 'year': '2019', 'unstructured': 'Saha JK, Hossain MS, Ghosh MK (2019) DFT study of response mechanism and ' 'selectivity of poly(3,4-ethylenedioxythiophene) towards CO2 and SO2 as ' 'gas sensor. Struct Chem 30:1427–1436', 'journal-title': 'Struct Chem'}, { 'key': '1776_CR14', 'unstructured': 'Frisch MJ, Trucks GW, Schlegel HB, Scuseria GE, Robb MA, Cheeseman JR, ' 'Scalmani G, Barone V, Petersson GA, Nakatsuji H, Li X, Caricato M, ' 'Marenich AV, Bloino J, Janesko BG, Gomperts R, Mennucci B, Hratchian HP, ' 'Ortiz JV, Izmaylov AF, Sonnenberg JL, Williams FD, Lipparini F, Egidi F, ' 'Goings J, Peng B, Petrone A, Henderson T, Ranasinghe D, Zakrzewski VG, ' 'Gao J, Rega N, Zheng G, Liang W, Hada M, Ehara M, Toyota K, Fukuda R, ' 'Hasegawa J, Ishida M, Nakajima T, Honda Y, Kitao O, Nakai H, Vreven T, ' 'Throssell K, Montgomery Jr JA, Peralta JE, Ogliaro F, Bearpark MJ, Heyd ' 'JJ, Brothers EN, Kudin KN, Staroverov VN, Keith TA, Kobayashi R, Normand ' 'J, Raghavachari K, Rendell AP, Burant JC, Iyengar SS, Tomasi J, Cossi M, ' 'Millam JM, Klene M, Adamo C, Cammi R, Ochterski JW, Martin RL, Morokuma ' 'K, Farkas O, Foresman JB, Fox DJ (2016) Gaussian 16, Wallingford, CT'}, { 'key': '1776_CR15', 'doi-asserted-by': 'publisher', 'first-page': '3684', 'DOI': '10.1063/1.448118', 'volume': '81', 'author': 'HJC Berendsen', 'year': '1984', 'unstructured': 'Berendsen HJC, Postma JPM, van Gunsteren WF, DiNola A, Haak JR (1984) ' 'Molecular dynamics with coupling to an external bath. J Chem Phys ' '81:3684–3690', 'journal-title': 'J Chem Phys'}, { 'key': '1776_CR16', 'doi-asserted-by': 'publisher', 'first-page': '8577', 'DOI': '10.1063/1.470117', 'volume': '103', 'author': 'U Essmann', 'year': '1995', 'unstructured': 'Essmann U, Perera L, Berkowitz ML, Darden T, Lee H, Pedersen LG (1995) A ' 'smooth particle mesh Ewald method. J Chem Phys 103:8577–8593', 'journal-title': 'J Chem Phys'}, { 'key': '1776_CR17', 'doi-asserted-by': 'publisher', 'first-page': 'e32938', 'DOI': '10.1371/journal.pone.0032938', 'volume': '7', 'author': 'X-H Yuan', 'year': '2012', 'unstructured': 'Yuan X-H, Wang Y-C, Jin W-J, Zhao B-B, Chen C-F, Yang J, Wang J-F, Guo ' 'Y-Y, Liu J-J, Zhang D, Gong L-L, He Y-W (2012) Structure-based ' 'high-throughput epitope analysis of hexon proteins in B and C species ' 'human adenoviruses (HAdVs). PLoS One 7:e32938', 'journal-title': 'PLoS One'}, { 'key': '1776_CR18', 'doi-asserted-by': 'publisher', 'first-page': '845', 'DOI': '10.1093/bioinformatics/btt055', 'volume': '29', 'author': 'S Pronk', 'year': '2013', 'unstructured': 'Pronk S, Páll S, Schulz R, Larsson P, Bjelkmar P, Apostolov R, Shirts ' 'MR, Smith JC, Kasson PM, van der Spoel D, Hess B, Lindahl E (2013) ' 'GROMACS 4.5: a high-throughput and highly parallel open source molecular ' 'simulation toolkit. Bioinformatics 29:845–854', 'journal-title': 'Bioinformatics'}, { 'key': '1776_CR19', 'doi-asserted-by': 'publisher', 'first-page': '3257', 'DOI': '10.1021/ct300400x', 'volume': '8', 'author': 'RB Best', 'year': '2012', 'unstructured': 'Best RB, Zhu X, Shim J, Lopes PEM, Mittal J, Feig M, MacKerell AD (2012) ' 'Optimization of the additive CHARMM all-atom protein force field ' 'targeting improved sampling of the backbone ϕ, ψ and side-chain χ1 and ' 'χ2 dihedral angles. J Chem Theory Comput 8:3257–3273', 'journal-title': 'J Chem Theory Comput'}], 'container-title': 'Structural Chemistry', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11224-021-01776-0.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/article/10.1007/s11224-021-01776-0/fulltext.html', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://link.springer.com/content/pdf/10.1007/s11224-021-01776-0.pdf', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2021, 9, 1]], 'date-time': '2021-09-01T11:23:05Z', 'timestamp': 1630495385000}, 'score': 1, 'resource': {'primary': {'URL': 'https://link.springer.com/10.1007/s11224-021-01776-0'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 4, 12]]}, 'references-count': 19, 'journal-issue': {'issue': '5', 'published-print': {'date-parts': [[2021, 10]]}}, 'alternative-id': ['1776'], 'URL': 'http://dx.doi.org/10.1007/s11224-021-01776-0', 'relation': { 'has-preprint': [ { 'id-type': 'doi', 'id': '10.21203/rs.3.rs-160254/v1', 'asserted-by': 'object'}]}, 'ISSN': ['1040-0400', '1572-9001'], 'subject': [], 'container-title-short': 'Struct Chem', 'published': {'date-parts': [[2021, 4, 12]]}, 'assertion': [ { 'value': '15 January 2021', 'order': 1, 'name': 'received', 'label': 'Received', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '30 March 2021', 'order': 2, 'name': 'accepted', 'label': 'Accepted', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, { 'value': '12 April 2021', 'order': 3, 'name': 'first_online', 'label': 'First Online', 'group': {'name': 'ArticleHistory', 'label': 'Article History'}}, {'order': 1, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Declarations'}}, { 'value': 'The authors declare no conflict of interest.', 'order': 2, 'name': 'Ethics', 'group': {'name': 'EthicsHeading', 'label': 'Conflict of interest'}}, { 'value': 'This content has been made available to all.', 'name': 'free', 'label': 'Free to read'}]}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit